Combined preparation of a thiazide diuretic and a loop diuretic
AssigneeHexal AG
InventorsHeinrich Knauf, Ernst Mutschler
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but the undesired secondary effects regarding potassium and magnesium losses are significantly reduced as well. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic.
Claims20
A combination preparation, comprising, jointly or separately from each other, a thiazide diuretic and a loop diuretic, wherein the thiazide diuretic is selected from the group consisting of:
- hydrochlorothiazide in an amount of from 5 to 50 mg;
- hydroflumethiazide in an amount of from 5 to 50 mg;
- benzthiazide in an amount of from 5 to 50 mg;
- chlorthalidone in an amount of from 5 to 50 mg;
- quinethazone in an amount of from 5 to 50 mg;
- bendroflumethiazide in an amount of from 0.5 to 5 mg;
- methychlothiazide in an amount of from 0.5 to 5 mg;
- indapamide in an amount of from 0.25 to 1.25 mg;
- polythiazide in an amount of from 0.2 to 2 mg;
- trichlormethazide in an amount of from 0.2 to 2 mg;
- and the loop diuretic is selected from the group consisting of:
- torasemide in an amount of from 2.5 to 15 mg;
- piretanide in an amount of from 2.5 to 15 mg;
- furosemide in an amount of from 7.5 to 37.5 mg;
- and
- bumetanide in an amount of from 0.05 to 0.3 mg.
- and from pharmaceutically acceptable derivatives of said thiazide diuretics and loop diuretics.
A method of using a combination preparation of a thiazide diuretic and a loop diuretic for the treatment of hypertension or heart failure, wherein the thiazide diuretic is selected from the group consisting of:
- hydrochlorothiazide in an amount of from 5 to 50 mg;
- hydroflumethiazide in an amount of from 5 to 50 mg;
- benzthiazide in an amount of from 5 to 50 mg;
- chlorthalidone in an amount of from 5 to 50 mg;
- quinethazone in an amount of from 5 to 50 mg;
- bendroflumethiazide in an amount of from 0.5 to 5 mg;
- metolazone in an amount of from 0.5 to 5 mg;
- methychlothiazide in an amount of from 0.5 to 5 mg;
- indapamide in an amount of from 0.25 to 1.25 mg;
- polythiazide in an amount of from 0.2 to 2 mg;
- trichlormethazide in an amount of from 0.2 to 2 mg;
- and the loop diuretic is selected from the group consisting of:
- torasemide in an amount of from 2.5 to 15 mg;
- piretanide in an amount of from 2.5 to 15 mg;
- furosemide in an amount of from 7.5 to 45 mg;
- and
- bumetanide in an amount of from 0.05 to 0.3 mg.
- and from pharmaceutically acceptable derivatives of said thiazide diuretics and loop diuretics.
Dependencies are inferred from the claim text.